论文部分内容阅读
采用血小板膜表面抗人活化血小板α颗粒膜蛋白（ＧＭＰ－１４０）单克隆抗体ＳＺ－５１，以放射免疫法，检测２４例急性心肌梗塞（ＡＭＩ）患者发病１周内的血小板膜表面ＧＭＰ－１４０、血浆凝血烷Ｂ_２（血栓素Ｂ_２，ＴＸＢ_２）和６－酮－前列腺素Ｆ_（１α）（６－ｋｅｔｏ－ＰＧＦ_（１α））的动态变化，并与２０例健康人对照。ＡＭＩ的ＧＭＰ－１４０、ＴＸＢ_２和６－ｋｅｔｏ－ＰＧＦ_（１α）在发病早期已明显增高，４８ｈ达高峰，以后呈逐渐下降的规律性变化，这表明ＡＭＩ早期，血小板高度活化。ＴＸＢ_２和６－ｋｅｔｏ－ＰＧＦ_（１α）与ＧＭＰ－１４０正相关。梗塞范围广、病情重时，这三项指标增高更为显著。这提示，检测上述指标对监护病情，以及评估预后可能有辅助参考价值，并为发病早期选用抗血小板活性药物提供了客观依据。
Platelet membrane surface anti-human activated platelet α-granule membrane protein (GMP-140) monoclonal antibody SZ-51 was used to detect platelet surface GMP-140 in 24 patients with acute myocardial infarction (AMI) within 1 week by radioimmunoassay , Plasma thromboxane B2 (TXB2) and 6-keto-PGF1 (1α) in 20 healthy subjects. The levels of GMP-140, TXB_2 and 6-keto-PGF_ (1α) in AMI were significantly higher in early onset and peaked at 48h, and then gradually decreased. This showed that platelets were highly activated in AMI. TXB_2 and 6-keto-PGF_ (1α) were positively correlated with GMP-140. A wide range of infarctions, severe illness, these three indicators increased more significantly. This suggests that the detection of these indicators on the guardianship of the disease, as well as assess the prognosis may have ancillary reference value, and for the early onset of anti-platelet active drugs provide an objective basis.